Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nucleix Ltd.
This is a prospective, case-control, multi-center, observational nonsignificant risk study. The study aims to collect blood and clinical data from subjects undergoing Low Dose CT (LDCT) for lung cancer screening and subjects with confirmed lung cancer.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Current or past smokers, with at least 20 pack-years
Subjects with either A high suspicion for lung cancer, with planned surgery to establish a definitive diagnosis within 60 days after date of blood collection OR treatment naive lung cancer patients
\- Current or past smokers, with at least 20 pack-years, undergoing LDCT for lung cancer screening
You may not be if
Known diagnosis or treatment of any previous cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
Current lung cancer is known to be stage III or IV by pathology.
Known diagnosis or treatment of any cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
Subjects whose purpose of performing LDCT is for surveillance of a lung nodule
Clareo Health | Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
